Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency

BK. Burton, M. Balwani, F. Feillet, I. Barić, TA. Burrow, C. Camarena Grande, M. Coker, A. Consuelo-Sánchez, P. Deegan, M. Di Rocco, GM. Enns, R. Erbe, F. Ezgu, C. Ficicioglu, KN. Furuya, J. Kane, C. Laukaitis, E. Mengel, EG. Neilan, S....

. 2015 ; 373 (11) : 1010-20.

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15031303
E-resources Online Full text

NLK ProQuest Central from 1980-01-03 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1980-01-03 to 3 months ago
Health & Medicine (ProQuest) from 1980-01-03 to 3 months ago
Family Health Database (ProQuest) from 1980-01-03 to 3 months ago
Psychology Database (ProQuest) from 1980-01-03 to 3 months ago
Health Management Database (ProQuest) from 1980-01-03 to 3 months ago
Public Health Database (ProQuest) from 1980-01-03 to 3 months ago

Links

PubMed 26352813
DOI 10.1056/nejmoa1501365
Knihovny.cz E-resources

BACKGROUND: Lysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia. METHODS: In this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per kilogram of body weight every other week); the placebo-controlled phase of the study was 20 weeks long and was followed by open-label treatment for all patients. The primary end point was normalization of the alanine aminotransferase level. Secondary end points included additional disease-related efficacy assessments, safety, and side-effect profile. RESULTS: Substantial disease burden at baseline included a very high level of low-density lipoprotein cholesterol (≥190 mg per deciliter) in 38 of 66 patients (58%) and cirrhosis in 10 of 32 patients (31%) who underwent biopsy. A total of 65 of the 66 patients who underwent randomization completed the double-blind portion of the trial and continued with open-label treatment. At 20 weeks, the alanine aminotransferase level was normal in 11 of 36 patients (31%) in the sebelipase alfa group and in 2 of 30 (7%) in the placebo group (P=0.03), with mean changes from baseline of -58 U per liter versus -7 U per liter (P<0.001). With respect to prespecified key secondary efficacy end points, we observed improvements in lipid levels and reduction in hepatic fat content (P<0.001 for all comparisons, except P=0.04 for triglycerides). The number of patients with adverse events was similar in the two groups; most events were mild and were considered by the investigator to be unrelated to treatment. CONCLUSIONS: Sebelipase alfa therapy resulted in a reduction in multiple disease-related hepatic and lipid abnormalities in children and adults with lysosomal acid lipase deficiency. (Funded by Synageva BioPharma and others; ARISE ClinicalTrials.gov number, NCT01757184.).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031303
003      
CZ-PrNML
005      
20170509071548.0
007      
ta
008      
151005s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1056/NEJMoa1501365 $2 doi
035    __
$a (PubMed)26352813
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Burton, Barbara K $u From the Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago (B.K.B.); Icahn School of Medicine, Mount Sinai, New York (M.B.), and Women and Children's Hospital of Buffalo, Buffalo (R.E.) - both in New York; Centre Hospitalier Universitaire Brabois-Hôpital d'Enfants, Vandoeuvre-lès-Nancy (F.F.), and University Hospital Necker-Enfants Malades and Imagine Institute, Paris (V.V.) - both in France; University Hospital Center Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia (I.B.); Cincinnati Children's Hospital Medical Center, Cincinnati (T.A.B.); Hospital Universitario La Paz, Madrid (C.C.G.); Ege University Medical Faculty, Izmir (M.C.), and Gazi University Medical Faculty, Ankara (F.E.) - both in Turkey; Hospital Infantil de México Federico Gómez, Mexico City (A.C.-S.); Cambridge University Hospitals, Cambridge, United Kingdom (P.D.); Unit of Rare Diseases, Department of Pediatrics, Gaslini Institute, Genoa (M.D.R.), and University of Padua, Padua (M.S.) - both in Italy; Stanford University, Palo Alto (G.M.E.), and University of California, San Francisco, San Francisco ( J.K.) - both in California; Children's Hospital of Philadelphia, Philadelphia (C.F.); Alfred I. duPont Hospital for Children, Wilmington, DE (K.N.F.); University of Arizona Cancer Center, Tucson (C.L.); Villa Metabolica, Center of Pediatric and Adolescent Medicine, University of Mainz, Mainz (E.M.), and University Hospital Freiburg, Freiburg (K.O.S.) - both in Germany; Boston Children's Hospital, Boston (E.G.N.), and Synageva BioPharma, Lexington (Y.Y., S.E., S.R.-C., A.G.Q.) - both in Massachusetts; John Hunter Children's Hospital, and Discipline of Paediatrics and Child Health, University of Newcastle, Newcastle, NSW (S.N.), Royal Children's Hospital, Parkville, VIC (H.P.), and Royal Brisbane and Women's Hospital, Brisbane, QLD (M.W.) - all in Australia; Faculty Hospital, Palacky University, Olomouc, Czech Republic
245    12
$a A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency / $c BK. Burton, M. Balwani, F. Feillet, I. Barić, TA. Burrow, C. Camarena Grande, M. Coker, A. Consuelo-Sánchez, P. Deegan, M. Di Rocco, GM. Enns, R. Erbe, F. Ezgu, C. Ficicioglu, KN. Furuya, J. Kane, C. Laukaitis, E. Mengel, EG. Neilan, S. Nightingale, H. Peters, M. Scarpa, KO. Schwab, V. Smolka, V. Valayannopoulos, M. Wood, Z. Goodman, Y. Yang, S. Eckert, S. Rojas-Caro, AG. Quinn,
520    9_
$a BACKGROUND: Lysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia. METHODS: In this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per kilogram of body weight every other week); the placebo-controlled phase of the study was 20 weeks long and was followed by open-label treatment for all patients. The primary end point was normalization of the alanine aminotransferase level. Secondary end points included additional disease-related efficacy assessments, safety, and side-effect profile. RESULTS: Substantial disease burden at baseline included a very high level of low-density lipoprotein cholesterol (≥190 mg per deciliter) in 38 of 66 patients (58%) and cirrhosis in 10 of 32 patients (31%) who underwent biopsy. A total of 65 of the 66 patients who underwent randomization completed the double-blind portion of the trial and continued with open-label treatment. At 20 weeks, the alanine aminotransferase level was normal in 11 of 36 patients (31%) in the sebelipase alfa group and in 2 of 30 (7%) in the placebo group (P=0.03), with mean changes from baseline of -58 U per liter versus -7 U per liter (P<0.001). With respect to prespecified key secondary efficacy end points, we observed improvements in lipid levels and reduction in hepatic fat content (P<0.001 for all comparisons, except P=0.04 for triglycerides). The number of patients with adverse events was similar in the two groups; most events were mild and were considered by the investigator to be unrelated to treatment. CONCLUSIONS: Sebelipase alfa therapy resulted in a reduction in multiple disease-related hepatic and lipid abnormalities in children and adults with lysosomal acid lipase deficiency. (Funded by Synageva BioPharma and others; ARISE ClinicalTrials.gov number, NCT01757184.).
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alanintransaminasa $x krev $7 D000410
650    _2
$a biopsie $7 D001706
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a HDL-cholesterol $x krev $7 D008076
650    _2
$a LDL-cholesterol $x krev $7 D008078
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a dyslipidemie $x farmakoterapie $x genetika $7 D050171
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a játra $x účinky léků $x patologie $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a sterolesterasa $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D002787
650    _2
$a Wolmanova nemoc $x krev $x farmakoterapie $7 D015223
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Balwani, Manisha
700    1_
$a Feillet, François
700    1_
$a Barić, Ivo
700    1_
$a Burrow, T Andrew
700    1_
$a Camarena Grande, Carmen
700    1_
$a Coker, Mahmut
700    1_
$a Consuelo-Sánchez, Alejandra
700    1_
$a Deegan, Patrick
700    1_
$a Di Rocco, Maja
700    1_
$a Enns, Gregory M
700    1_
$a Erbe, Richard
700    1_
$a Ezgu, Fatih
700    1_
$a Ficicioglu, Can
700    1_
$a Furuya, Katryn N
700    1_
$a Kane, John
700    1_
$a Laukaitis, Christina
700    1_
$a Mengel, Eugen
700    1_
$a Neilan, Edward G
700    1_
$a Nightingale, Scott
700    1_
$a Peters, Heidi
700    1_
$a Scarpa, Maurizio
700    1_
$a Schwab, K Otfried
700    1_
$a Smolka, Vratislav
700    1_
$a Valayannopoulos, Vassili
700    1_
$a Wood, Marnie
700    1_
$a Goodman, Zachary D., $d 1946- $7 xx0213225
700    1_
$a Yang, Yijun
700    1_
$a Eckert, Stephen
700    1_
$a Rojas-Caro, Sandra
700    1_
$a Quinn, Anthony G
773    0_
$w MED00003517 $t The New England journal of medicine $x 1533-4406 $g Roč. 373, č. 11 (2015), s. 1010-20
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26352813 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20170509071923 $b ABA008
999    __
$a ok $b bmc $g 1092179 $s 914429
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 373 $c 11 $d 1010-20 $i 1533-4406 $m The New England journal of medicine $n N Engl J Med $x MED00003517
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Archiving options